Article
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
International journal of cancer - 1 Nov 2020
Jiang Shiyu, Qin Yan, Jiang Hongxin, Liu Biao, Shi Jianming, Meng Fanlu, Liu Peng, Yang Jianliang, Yang Sheng, He Xiaohui, Zhou Shengyu, Gui Lin, Liu Hao, Lin Jing, Han-Zhang Han, Shi Yuankai
Abstract excerpt
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.